Equities research analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post ($0.26) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Seres Therapeutics’ earnings, with estimates ranging from ($0.30) to ($0.22). Seres Therapeutics reported earnings per share of ($0.52) in the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is expected to report its next quarterly earnings results on Wednesday, March 4th.
On average, analysts expect that Seres Therapeutics will report full year earnings of ($1.26) per share for the current year, with EPS estimates ranging from ($1.37) to ($1.20). For the next financial year, analysts anticipate that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($0.95) to ($0.51). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.03. The business had revenue of $7.03 million for the quarter, compared to analyst estimates of $6.69 million.
NASDAQ:MCRB traded down $0.05 during trading hours on Friday, reaching $3.43. 265,155 shares of the company’s stock were exchanged, compared to its average volume of 218,759. The firm has a market capitalization of $243.64 million, a price-to-earnings ratio of -2.17 and a beta of 1.78. The company has a 50-day moving average of $3.74 and a 200 day moving average of $3.47. Seres Therapeutics has a 1-year low of $2.02 and a 1-year high of $8.39.
A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in Seres Therapeutics during the 3rd quarter worth $215,000. Barclays PLC raised its position in Seres Therapeutics by 36.5% during the 3rd quarter. Barclays PLC now owns 19,737 shares of the biotechnology company’s stock worth $79,000 after buying an additional 5,278 shares during the last quarter. California State Teachers Retirement System raised its position in Seres Therapeutics by 72.3% during the 3rd quarter. California State Teachers Retirement System now owns 56,844 shares of the biotechnology company’s stock worth $228,000 after buying an additional 23,862 shares during the last quarter. State Street Corp raised its position in Seres Therapeutics by 24.9% during the 3rd quarter. State Street Corp now owns 573,351 shares of the biotechnology company’s stock worth $2,299,000 after buying an additional 114,375 shares during the last quarter. Finally, Voya Investment Management LLC raised its position in Seres Therapeutics by 35.1% during the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock worth $55,000 after buying an additional 3,555 shares during the last quarter. Institutional investors own 91.86% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
See Also: Analyst Ratings Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.